Inhibikase Therapeutics
IKT | NASDAQ
$1.45
-$0.07 (-4.61%)
At close: Nov 16, 2026, 4:00 PM ET
$1.45
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
-4.61%
(1D)No price chart data available for 1D timeframe.
Rating
35.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #645/1021 (Top 63%)
Key Statistics
Market Data
Market Cap $285.56M
1D Range
1.45 1.57
52W Range
1.41 2.52
Valuation (TTM)
PE -3.22
PB 1.51
EV/EBITDA -1.33
Valuation (NTM)
Forward PE N/A
Forward PEG 0.23
Price Target $5.00
Cash Flow
FCF Yield -17.4%
SBC Adj. FCF Yield -24.8%
SBC Impact -42.1%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -150.0% |
-58.0%
Dil EPS 3Y | 5Y 79.2% |
42.7%
FCF 3Y | 5Y -52.7% |
-27.4%
Returns
ROA -34.3%
ROE -40.5%
ROIC -39.9%
Financial Health
Net Cash
$193.32M
Current Ratio 15.34
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arteria...
Sector Healthcare
Industry Biotechnology
Employees 35
IPO Date Dec 23, 2020
Website www.inhibikase.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Hold
Price Target
$5.00
Upside
+244.83%
Buy (1)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove IKT